Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Biogen

Gilead Sciences

Inovio Pharmaceuticals

Eli Lilly

Mallinckrodt PLC

Vir Biotechnology

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

Aytu BioScience

Can-Fite BioPharma Ltd.

Enanta Pharmaceuticals

La Jolla Pharmaceutical

OPKO Health

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

Roche's (RHHBY) cobas SARS-CoV-2 Test for the qualitative detection of SARS-CoV-2, the virus that causes the COVID-19 disease, gets EUA from the FDA.

Roche's (RHHBY) Coronavirus Test Achieves EUA From the FDA

The U.S. Food and Drug Administration (FDA) issued emergency authorization for a faster coronavirus test made by Swiss diagnostics maker Roche  and allowed New York state to authorize certain labs to test for the virus, moves aimed at boosting screening capacity to help contain the growing epidemic.

FDA works to speed coronavirus tests with Roche, New York approvals

The U.S. Food and Drug and Administration has granted emergency approval for use of a new test that can increase the range of testing patients by up to 10 times compared to methods in use currently, Bloomberg reports.

FDA approves new Coronavirus test that could speed rate of testing up to tenfold

Shares of Swiss diagnostics and pharmaceutical giant Roche soared 11% after the U.S. Food and Drug Administration (FDA) issued emergency authorization for their COVID-19 test.

Shares of Swiss drugmaker Roche up 11% after FDA approval for coronavirus test

Roche Holding AG (OTC: RHHBY) announced Friday that the FDA has issued an emergency use authorization for its cobas SARS-CoV-2 test, which aims to speed up the ability to test patients for the coronavirus.

Roche's Faster Coronavirus Test Receives FDA Emergency Use Authorization

The Food and Drug Administration (FDA) has given emergency approval for Roche's new coronavirus test that could increase the speed of testing for the virus tenfold.

FDA Approves Emergency New Coronavirus Test To Boost Screening In The U.S.

The U.S. Food and Drug Administration issued emergency authorization for a coronavirus test made by Swiss diagnostics maker Roche, a move aimed at boosting screening capacity to help contain the growing epidemic.

US approves Roche coronavirus test in the race to boost screening capacity

The drug, usually used to treat rheumatoid arthritis, could help prevent catastrophic organ failure in coronavirus patients.

China Approves a Treatment for COVID-19 Complications

Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.

Roche's Esbriet Gets FDA Breakthrough Tag for New Indication

Editas Medicine

Xenon Pharmaceuticals

If you can handle the uncertainty, these small-cap stocks can make you very wealthy.

3 High-Risk, High-Reward Stocks That Have Massive Upside Potential

Roche Holding’s revenue grew at a CAGR of 5.3% from $52.5 billion in 2015 to $64.4 billion in 2019, and it is estimated to top $66 billion in 2020, led by its Neuroscience drugs. The company’s oncology drugs will account for 45% of the company’s total sales in 2020, but Neuroscience drugs are key.

Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience

NICE recommended that the country's National Health Service not prescribe Polivy.

U.K. Regulatory Advisor Rejects Roche Cancer Drug

Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.

Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review

It's another win for the promising treatment.

FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq

Analog Devices

Analog Devices, Inc. (ADI) CEO Vincent Roche on Q1 2020 Results - Earnings Call Transcript

Our price estimate for Roche Holding’s ADR is $48, which is at a premium of around 10% to the current market price. Our price estimate is based on expected 2020 earnings of $2.61 on an adjusted basis, and a price to earnings multiple of 18.5x.

10% Upside For Roche’s ADR?

Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.

Roche Reports Disappointing Data on Alzheimer's Disease Drug

Lilly and Roche reported their latest disappointments in attempting to effectively treat Alzheimer's by attacking amyloid plaques.

A Double Failure of Alzheimer's Drugs

If candidate drug risdiplam is approved, it could be a major competitor to treatments already developed by Biogen and Novartis.

Roche Presents Spinal Muscular Atrophy Drug Data

Hanover Insurance Group, Inc. (THG) CEO John Roche on Q4 2019 Results - Earnings Call Transcript

Moderna

Some of the biopharma industry's biggest names are taking important steps to combat the world's latest public health emergency.

3 Big Drugmakers Are Taking On the Coronavirus

Roche Holding AG (RHHBY) CEO Severin Schwan on Q4 2019 - Earnings Call Transcript

Its newer drugs are more than making up for the waning sales of older medications.

News for Roche Holding AG Stock (RHHBY)